[Evaluation of the therapeutic spectrum of entumine-chloro-2-11-dibenzothiazepine. A study based on 50 clinical cases].
D000978:Antiparkinson Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D003072:Cognition Disorders / Q000188:drug therapy; D003863:Depression / Q000139:chemically induced / Q000188:drug therapy; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D007361:Intelligence Tests; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D009069:Movement Disorders / Q000139:chemically induced; D009765:Obesity / Q000139:chemically induced; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011581:Psychological Tests; D012559:Schizophrenia / Q000188:drug therapy
D000978:Antiparkinson Agents; D003987:Dibenzothiazepines; D010879:Piperazines
Evaluation du spectrum thérapeutique de l'entumine-chloro-2-11-dibenzothiazepine.